SCFE Longitudinal International Prospective Registry (SLIP)

SLIP Registry - SCFE Longitudinal International Prospective Registry

Slipped Capital Femoral Epiphysis (SCFE) is the most common disorder of the adolescent hip and diagnosis and treatment of SCFE remain areas of controversy and investigation. The current issues relating to diagnosis stem from an inability to diagnose the condition early on, resulting in increased morbidity. Once diagnosed, there are multiple different options for surgical treatment, including in-situ pinning, and the Modified Dunn procedure. Research is ongoing to determine the parameters that should be considered when selecting a procedure to ensure an ideal outcome. In particular, there is a focus on investigating which treatment method may result in lower incidence of avascular necrosis of the femoral head and femoroacetabular impingement (FAI), two significant long term concerns associated with SCFE. Despite myriad published studies on SCFE, very few are prospective and most lack sufficient patient numbers for clinically meaningful comparative analysis. The aim of this study is to develop a multi-center, international prospective registry of patients with SCFE to facilitate the comprehensive examination of clinical, functional and radiographic outcomes of each treatment, in relation to specific parameters determined prior to intervention. The general registry will serve as a hypothesis-generating database of prospectively collected outcomes. In turn, this will facilitate the development of targeted, hypothesis-testing randomized controlled trials and observational studies that can be housed within the larger registry.

Study Overview

• Status: Recruiting
• Conditions: Slipped Capital Femoral Epiphyses; SCFE
• Intervention / Treatment: Other: Observational

• Study Type: Observational
• Enrollment (Estimated): 2000

Contacts and Locations

• Study Contact: Name: Kishore Mulpuri, FRCSC; Phone Number: (604) 875-2054; Email: kmulpuri@cw.bc.ca
• Study Contact Backup: Name: Ashley L Munoz, BSc; Phone Number: (604) 875-2359; Email: ashley.munoz@cw.bc.ca

Study Locations

• Canada
  • British Columbia
    • Vancouver, British Columbia, Canada, V6H 3N1
      • Recruiting
      • British Columbia Children's Hospital
      • Contact: Emily K Schaeffer, PhD; Phone Number: 6048752359; Email: emily.schaeffer@cw.bc.ca
      • Contact: Ashley L Munoz, BSc; Phone Number: 6048752359; Email: ashley.munoz@cw.bc.ca
      • Principal Investigator: Kishore Mulpuri, MSc
      • Sub-Investigator: Emily K Schaeffer, PhD

Participation Criteria

Eligibility Criteria

• Ages Eligible for Study: 1 second to 18 years (Child, Adult)
• Accepts Healthy Volunteers: No

• Sampling Method: Probability Sample

Study Population

Patients who have been diagnosed with SCFE and receive follow-up at a participating centre will be included in the registry. Patients will be enrolled during one of their routine clinic appointments at one of the participating centers.

Description

Inclusion Criteria:

• Confirmed diagnosis of SCFE
• Intend to receiving follow-up at participating centre
• Less than 18 years old at time of admission
• Adequate diagnostic information and radiographic imaging (for patients previously treated for SCFE)

Exclusion Criteria:

• No definitive diagnosis of SCFE
• Do not intend to receive follow-up at a participating centre
• Greater than 18 years old at time of admission
• Prior treatment for SCFE not appropriately documented
• Known or suspected underlying conditions (e.g., cerebral palsy, spina bifida, or osteogenesis imperfecta)

Study Plan

How is the study designed?

Number of groups / cohorts

3

Cohorts and Interventions

Group / Cohort	Intervention / Treatment
Arm I: Prospective from diagnosis; Patients have been enrolled and followed since diagnosis will be placed into Arm I.	Other: Observational; All groups will undergo observational data collection. No interventions will be made to patient care.
Arm II: Prior treatment at centre; Patients who have received previous treatment and will continue to receive treatment at the participating center will be placed into Arm II.	Other: Observational; All groups will undergo observational data collection. No interventions will be made to patient care.
Arm III: Prior treatment at outside centre; Patients who have received previous treatment at an outside center but are continuing treatment at a participating center will be placed into Arm III.	Other: Observational; All groups will undergo observational data collection. No interventions will be made to patient care.

What is the study measuring?

Primary Outcome Measures

Outcome Measure	Time Frame
Development of a multi-centre, general, prospective SCFE registry, with follow-up to skeletal maturity	Until study completion in 2028
Comparison of the clinical, functional, and radiographic parameters related to SCFE in the context of treatment outcomes	Until study completion in 2028
Examination of the long-term outcome of prophylactically pinning the contralateral hip, specifically in regards to development of avascular necrosis	Until study completion in 2028
Determination of whether prophylactic fixation allows for preservation of hip morphology and function in the short and long term	Until study completion in 2028
Comparative analysis of surgical treatment outcomes, with particular regard to complications (avascular necrosis, femoroacetabular impingement (FAI), secondary surgeries)	Until study completion in 2028
Comparison of mild SCFE treatment with or without acute FAI treatment in regard to complication and short-term outcomes	Until study completion in 2028
Examination of timelines and results of diagnostic tests leading to the diagnosis of SCFE	Until study completion in 2028
Determination of the timeline for patients to return to full weight-bearing following treatment and to assess the level to which they return to activity	Until study completion in 2028

Collaborators and Investigators

• Sponsor: University of British Columbia
• Investigators: Principal Investigator: Kishore Mulpuri, FRCSC, Principal Investigator

Study record dates

Study Major Dates

• Study Start (Actual): May 30, 2018
• Primary Completion (Estimated): May 1, 2028
• Study Completion (Estimated): May 1, 2028

Study Registration Dates

• First Submitted: October 2, 2019
• First Submitted That Met QC Criteria: October 3, 2019
• First Posted (Actual): October 7, 2019

Study Record Updates

• Last Update Posted (Actual): April 5, 2024
• Last Update Submitted That Met QC Criteria: April 3, 2024
• Last Verified: April 1, 2024

More Information

Terms related to this study

• Additional Relevant MeSH Terms: Musculoskeletal Diseases; Bone Diseases; Bone Diseases, Developmental; Osteochondrodysplasias; Epiphyses, Slipped; Slipped Capital Femoral Epiphyses
• Other Study ID Numbers: H15-03132

Plan for Individual participant data (IPD)

• Plan to Share Individual Participant Data (IPD)?: NO

Drug and device information, study documents

• Studies a U.S. FDA-regulated drug product: No
• Studies a U.S. FDA-regulated device product: No